'Ned' Sharpless and 'Ned' David form Jupiter Bioventures to quickly test out, and if necessary discard, ideas in biotech.
Even as more health systems adopt ambient scribes, the technology providers might find it harder to differentiate themselves, analysts say.
The FDA's digital health advisory committee is expected to weigh in on how generative AI should be regulated by the agency.
Kennedy's nonprofit, Children’s Health Defense, is involved in vaccine lawsuits against agencies he could wind up overseeing
The new formulation could help secure a larger share of the blockbuster's sales after the cancer drug's U.S. patent expires in 2028.
While RFK Jr. has been a vocal critic of pharma, BioNTech and Bristol Myers Squibb execs sought to project calm about Trump's pick for HHS.
High-quality manufactured drugs should not become products that only certain patients can afford, writes former FDA Commissioner Scott Gottlieb.
